Summary
Malotilate, a hepatotropic agent, was given to 39 cirrhotic patients for more than 32 weeks. The serial changes in the serum levels of hepatic fibrogenesis markers, such as procollagen type III N-terminal peptides (P-III-N-P) and immunoreactive prolyl hydroxylase beta-subunit (IR-BPH) were analyzed. Serum albumin levels, transaminase and choline esterase activities and the Normotest values were found to be significantly improved by malotilate treatment. The levels of both serum markers of hepatic fibrogenesis were also significantly reduced by malotilate. The prognoses of the decompensated liver cirrhosis patients treated with malotilate were significantly better than those who did not receive malotilate. These results indicate that the effects of malotilate on chronic liver diseases are not simply biocosmetic, but rather are related to an improvement in the basal changes of the liver, including a decrease in the fibrogenetic stimulus. These effects of malotilate improved the prognosis of liver cirrhosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Imaizumi Y, Katoh M, Sugimoto T, et al: Effect of malotilate (diisopropyl 1, 3-dithiol-2-ylidenemalonate) on the protein synthesis in rat liver. Jpn J Pharmacol 1982;32:369–375
Igarashi S, Hatahara T, Funaki N: Effects of malotilate on protein synthesis in partially hepatectomized normal and cirrhotic rat livers. In: Oda T, Tygstrup N, eds. Hepatotrophic Agent Malotilate. Proceedings of a Symposium on Malotilate held at the 7th World Congress of Gastroenterology Stockholm, Excerpta Medica, Amsterdam. 1983;9–20
Suzuki H, Ichida F, Takino T, et al: Therapeutic effects of malotilate on chronic hepatitis and liver cirrhosis: A double blind, controlled multicenter trial. ibidIn:, 1983;54–68
Hirayama C, Kanai K: Effect of malotilate on serum albumin levels in patients with liver cirrhosis with special reference to the adjunctive therapeutic effect on albumin infusion. ibidIn:, 1983;69–76
Monna T: Effect of malotilate on experimental liver fibrosis (cirrhosis) induced by carbon tetrachloride or egg yolk sensitization. ibidIn:, 1983;44–53
Igarashi S, Hatahara T, Nagai Y, et al: Anti-fibrotic effect of malotilate on liver fibrosis induced by carbon tetrachloride in rats. Jpn J Exp Med 1986;56:235–245
Rohde H, Vargas L, Hahn E, et al: Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979;9:451–459
Kivirikko KI, Savolainen ER: Serum markers of hepatic collagen metabolism. Acta Hepat Jap 1985;26:1421–1425 (in Jpn)
Savolainen ER, Goldberg B, Leo MA, et al: Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcoholism: Clin Exp Res 1984;8:384–389
Galambos MR, Collins DC, Galambos JT: A radioimmunoassay procedure for type III procollagen: its use in the detection of hepatic fibrosis. Hepatology 1985;5:38–42
Savolainen ER, Risteli J, Miettinen TA, et al: Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. 1. Prolyl hydroxylase. Eur J Clin Invest 1979;9:89–95
Muragaki Y: Experimental study on alteration of collagen metabolism in liver fibrosis. J Wakayama Med Soc 1985;36:195–208 (in Jpn)
Matsuda Y, Yasuhara M, Takada A: Effects of malotilate on hepatic fibrogenesis in chronic liver diseases. In: International Committee of JSGE ed. New Trends in Peptic Ulcer and Chronic Hepatitis. Part II Chronic Hepatitis. Excerpta Medica, Tokyo, 1987;133–140
Yoshida S, Bai Y, Muragaki Y, et al: A sandwich immunoassay for human prolyl 4-hydroxylase using monoclonal antibody. Clin Chim Acta 1986;160:37–46
Nakaya H: Clinical significance of ICG Rmax measurement for quantitation of the total functioning hepatic cell mass. Acta Hepat Jap 1980;21:1614–1625 (in Jpn)
Paumgartner G, Probst P, Kraines R: Kinetics of indocyanine green removal from the blood. Ann NY Acad Sci 1970;170:134–146
Sato H, Matsuda Y, Takada A: Clinical significance of measurement of hepatic volume by computed tomography. Jap J Med Image 1984;3:723–731 (in Jpn)
Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958;8:699–712
Greenwood M: Reports on public health and medical subjects. No.33, Appendix 1, The errors of sampling of the survivorship tables. H.M. Stationery Office, London, 1926
Owren PA: Normotest in liver diseases. Farmakoterapi 1969;25:46–59
Cardinale GJ, Udenfriend S: Prolyl hydroxylase. Adv Enzymol 1974;41:245–300
Prockop DJ, Kivirikko KI, Tuderman L, et al: The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med 1979;301:13–23
Takeuchi T, Prockop DJ: Protocollagen proline hydroxylase in normal liver and in hepatic fibrosis. Gastroenterology 1969;56:744–750
Fuller GC, Nolan JC, Fink S, et al: Prolyl hydroxylase activity in normal and diseased human liver. Proc Soc Exp Biol Med 1976;151:61–64
Yasuhara M, Matsuda Y, Takada A: Clinical significance of serum prolyl hydroxylase β-subunit levels determined using monoclonal antibody. Jpn J Gastroenterol 1987;84:1225–1232 (in Jpn)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takase, S., Takada, A., Yasuhara, M. et al. Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterol Jpn 23, 639–645 (1988). https://doi.org/10.1007/BF02782949
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02782949